Furthermore, 157, 54, and 18 reports were published before 2019; 224, 49, and 41 were published between 2020 and 2022; and 132, 28, and 27 were published in or after 2023, respectively, showing an increasing trend in the number of reports for these cancers year by year.
← all excerpts
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
1
—
—